Glecirasib

Indicated For

KRAS G12C-mutated NSCLC

About This Medication

# Glecirasib Patient Guide: How to Get Glecirasib at Low or No Cost **Important Notice:** As of March 2026, Glecirasib (JAB-21822) is an investigational KRAS G12C inhibitor in clinical development for advanced solid tumors like NSCLC and pancreatic cancer. It is **not FDA-approved**, and no commercial patient assistance program exists from a manufacturer, as it remains in trials (e.g., NCT05009329).[1][2][5] This guide provides general information on accessing it via clinical trials or future programs. Always consult your oncologist for personalized advice. ## About Glecirasib Glecirasib is an oral medication taken once daily (800 mg) that targets the **KRAS G12C mutation**, a genetic change found in some lung, pancreatic, and other solid tumors. It works by locking the mutated KRAS protein in an inactive state, stopping cancer cell growth and promoting cell death.[1][3] Clinical trials show promising results: - In pancreatic cancer (PDAC), it achieved a 41.9% response rate, median progression-free survival of 5.6 months, and overall survival of 10.7 months.[1][3] - In NSCLC, it's in pivotal phase 2b/3 trials with good tolerability.[3][5] It's well-tolerated, with common side effects managed by dose adjustments. Trials exclude patients with certain conditions like active infections or prior KRAS G12C inhibitors.[2] Since it's not approved, access is primarily through clinical trials.[1][2][5] ## Who Qualifies for Access? Currently, no patient assistance program (PAP) offers free or low-cost Glecirasib outside trials, as there's no identified manufacturer-sponsored PAP (developer: Jacopo Pharma).[5] Eligibility focuses on trial enrollment: - Adults (≥18 years) with advanced/metastatic **KRAS G12C-mutant solid tumors** (e.g., NSCLC, PDAC) after standard treatments fail. - Good performance status (ECOG 0-1), life expectancy ≥3 months. - No prior KRAS G12C inhibitors, no active infections (HBV/HCV/HIV), no major heart issues.[2] ## Income Eligibility No income-based PAP exists yet. Trial participation is generally free (drug, monitoring covered), with no income thresholds. If approved commercially, PAPs typically use **Federal Poverty Level (FPL)** guidelines, e.g., 400-500% FPL. Here's a hypothetical table based on common US PAPs (2026 FPL estimates; actuals vary): | Household Size | 400% FPL | 500% FPL | |---------------|----------|----------| | Individual | $60,240 | $75,300 | | Couple | $81,760 | $102,200| | Family of 3 | $103,280| $129,100| | Family of 4 | $124,800| $156,000| **Notes:** Trials don't require income proof. Future PAPs may add insurance status.[5] ## Insurance Requirements Trials cover costs regardless of insurance. Commercially (if approved), PAPs often require: - No or inadequate coverage (e.g., high copays). - Medicare Part D patients may face restrictions; some PAPs bridge the 'donut hole'.[2] ## Step-by-Step Application Process ### For Clinical Trials (Primary Access): 1. **Confirm Eligibility:** Ask your doctor for **KRAS G12C testing** (biopsy/NGS). Use ClinicalTrials.gov (search 'glecirasib' or NCT05009329).[2] 2. **Find Sites:** Check active trials in NSCLC/PDAC (US/China/global).[1][5] 3. **Contact Investigator:** Provide consent; screening includes scans, bloodwork.[2] 4. **Enroll:** If eligible, receive drug free until progression/toxicity. ### For Future PAP (Hypothetical): 1. Visit manufacturer site (e.g., Jacopo Pharma) or call support. 2. Download application; submit income proof (tax returns), ID, prescription. 3. Doctor completes clinical forms. 4. Approval: 2-4 weeks; drug shipped to pharmacy/doctor. ## Timeline and Delivery - **Trial Screening:** 1-4 weeks. - **First Dose:** Upon enrollment; cycles every 21 days orally at home/clinic.[1] - **Monitoring:** Regular visits (scans every 6-9 weeks).[2] - Delivery: Oral pills; refills via trial pharmacy. Processing for hypothetical PAP: 10-30 days.[5] ## Alternatives if Denied or Ineligible - **Other KRAS G12C Inhibitors:** FDA-approved **sotorasib (Lumakras)** or **adagrasib (Krazati)** for NSCLC; check their PAPs (e.g., Amgen Safety Net, Mirati Access Program). Similar mechanism, ORR ~37%.[4] - **Biosimilars:** None listed. - **Trials:** Search for JAB-3312 combos or LY3537982.[4][5][6] - **General Help:** NeedyMeds.org, RxAssist.org, or PAN Foundation for copay aid. ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Glecirasib is experimental; risks/benefits discussed in trials. Consult your healthcare provider. Program details may change; verify via official sources. No warranty on accuracy. Word count: 912.

Program information last verified: March 30, 2026